India's First Dengue Vaccine: What You Need to Know About “Qdenga”

Nitika Saini
2 days ago
5 min read

For years, dengue has stood among the greatest public health challenges India has experienced seasonally. Every year when the monsoons set in, dengue cases increase nationwide, affecting healthcare systems and thousands of people. Even after breakthroughs in vaccine development for illnesses like COVID-19, HPV, and flu, dengue remained one of the major infections with no vaccine available in India.

But that's all over now. The Central Drugs Standard Control Organization (CDSCO) has approved India’s first dengue vaccine, Qdenga (TAK-003), for sale. Qdenga is developed by the pharmaceutical company Takeda GmbH, Germany, and will be imported by M/s Takeda Biopharmaceuticals India Pvt. Ltd. It is a huge step in preventive healthcare that can greatly reduce the number of dengue patients hospitalized each year.

Why India Has Taken So Long to Approve a Dengue Vaccine

Unlike other viral infections, preventing dengue using vaccinations has been complicated. The most significant scientific problem is the presence of four distinct virus strains (DENV-1, DENV-2, DENV-3, and DENV-4) within the dengue family. An individual who contracts one strain of the disease will acquire immunity to that particular strain alone but remain susceptible to the other three strains. Above all these facts, the cost of dengue vaccine in India now seems like a treatment worth the estimated price.

Worse still, there is a phenomenon called Antibody-Dependent Enhancement (ADE). During a subsequent infection by another strain of the virus, the presence of antibodies generated during the initial infection increases the chances of dengue complications.

All these aspects contributed to the complexity of the vaccine creation process compared to vaccines against a single virus strain. Moreover, early vaccines were unsafe for people not affected by the disease. Taking all these events into account, the Indian authorities have been cautious about any vaccine, with the need for strong evidence.

India's First Dengue Vaccine: Qdenga’s Origin and What Makes It Unique

Qdenga is a trade name of a medication known as TAK-003 produced by Takeda Pharmaceutical. Unlike other existing dengue vaccines, Qdenga does not require any blood tests to check if the person was infected before vaccination.

The drug is approved in over 42 countries globally and is prequalified by WHO concerning its quality, safety, and efficacy, achieving a strong global safety record. In addition, Takeda partners with Biological E, an Indian vaccine manufacturer, to boost production of Qdenga and plans to produce 50 million doses per year and 100 million per year globally by 2030. However, the Qdenga dengue vaccine price may still seem like a costly treatment for most people in India.

How Qdenga Works Against Dengue: Understanding Its Tetravalent Protection

Qdenga is a tetravalent attenuated vaccine as it contains all four strains of dengue virus. Apart from protecting from one specific strain of dengue virus, the vaccine protects against all four serotypes of the disease. Qdenga vaccination regimen comprises:

2 doses
0.5 ml per dose
3-month interval between doses

This tetravalent vaccine is especially necessary due to the circulation of all four types of dengue virus in India.

Clinical Trial Results and Effectiveness

Among the main factors leading to the approval of Qdenga include the robustness of its global clinical evidence. As per the data collected by the phase III clinical trial conducted by Takeda:

Efficacy of 80.2% in the case of laboratory-confirmed dengue, one year after the second dose.
Efficacy of 90.4% for dengue hospitalizations within 18 months.
It worked regardless of prior infection with dengue.

These results are very significant because reduced hospitalization leads to lower healthcare costs and deaths due to the disease.

Regulatory Approval for India: What Has Been Modified?

Qdenga has been approved by DCGI through CDSCO for use in individuals aged between 4 and 60 years. As reported by Takeda, the dengue vaccine availability in India can be expected during the first half of the year 2027 in private healthcare facilities after all necessary regulatory and marketing procedures have been completed.

Approval of the vaccine shows how drastically the strategy has changed. This is because India has been using mosquito prevention, health education campaigns, and hospital treatment for dengue to date.

Qdenga Vaccine Eligibility: Who Can Get It?

Understanding who can receive the vaccine is important for making informed decisions about dengue prevention. Here is the approved indication to help you better comprehend:

The eligible age range to get this vaccine is 4-60 years of age.
The approved dosing regimen is 2 doses.
To get this vaccine, prior history of dengue infection is not a requirement.
Any pre-vaccination screening is not required.
Vaccination must be done under professional guidance. This is required even though national immunization strategies may change as per new post-marketing data.

What This Approval Means for India's Public Health System

India has the most dengue cases, with reported cases increasing by 11 times in the last 20 years, according to Takeda. But now, the use of Qdenga can have the following benefits for public health:

Fewer cases of hospitalizations during monsoon epidemics.
Less pressure on the Emergency Department and ICUs.
Greater protection for children and the working-age population.
Decrease in healthcare treatment expenses due to severe dengue.
Stronger strategy for prevention and healthcare along with mosquito control.

Nevertheless, the experts mention that a vaccine may not solve the dengue problem since mosquitoes still spread the disease.

The Road Ahead: Challenges That Still Remain

Despite this historic accomplishment, there are certain challenges, such as:

The need for an affordable dengue vaccine price for universal access. This is because the estimated commercial Qdenga dengue vaccine price is set to fall between ₹3,000 and ₹6,000 per dose. This may probably make the two-dose regimen cost around ₹6,000 to ₹12,000 in a private healthcare facility.
The availability of this vaccine may not be limited to private medicine alone.
Increased awareness regarding eligibility and dosage among people still stands as a major concern.
Long-term monitoring for any safety and efficacy issues in Indian individuals.
Mosquito control has to be one of the greatest challenges among all, as dengue may not stop spreading unless the spreading agents are controlled.

Conclusion

India's battle against dengue will depend not just on access to a vaccine but also on how well it is used within public health policies. Also, the dengue vaccine price needs to fall in the affordable category for the poor and middle-class Indian households.

Dengue has been predictable during the monsoon season for years in the country. Rather than approving the product early, the authorities waited for better clinical proof due to the nature of the disease. This might have delayed the process, but it probably enhanced trust in the product.